Computing Power × Human Endeavor × R&D Capability: New Paradigm of Innovative Drug R&D in the AI Era Session Agenda Released
May 30,2026
Over the past two years, AI has emerged as one of the most closely watched factors in pharmaceutical R&D. However, for the innovative drug industry, the core question has never been whether AI can generate content. Instead, it lies in whether AI can integrate into real-world R&D workflows, support scientific decision-making, deliver quality-assured outputs, and gain genuine trust and adoption within heavily regulated, high-liability, and highly collaborative working environments.
On the afternoon of July 22, the session Computing Power ×Human Endeavor ×R&D Capability:New Paradigm of Innovative Drug R&D in the AI Era, co-hosted by Foxu.AI, Jeyou Pharma and the Shanghai Institute for Clinical Innovation & Translation, will take place during CPIC 2026.
This session will feature in-depth discussions covering key topics: AI medical technology evolving from technical concepts to clinical applications, the re-evolution of innovative drug R&D organizations in the AI era, the In Silico Workforce within highly regulated R&D environments, and the launch of industrialized trusted knowledge delivery scenarios built on Hospital GCP, Biotech, CRO and Foxu.AI.
Session Agenda
Co-host: Foxu.AI、Jeyou Pharma、Shanghai Academy of Clinical Innovation and Translational Science
AI Medical Technology: From Technical Concepts to Clinical Application
Qingsong Qin, Shanghai Institute for Clinical Innovation & Translation
Computing Power × Human Endeavor: Re-evolution of Innovative Drug R&D Organizations in the AI Era
Jianfeng Peng, Professor of Renmin University of China; Chairman, China Stone
In Silico Workforce in Highly Regulated R&D Scenarios: From Report Generation to Process Quality Control
Hongming Liang, Co-founder & Chief Scientist, Foxu.AI
Hospital GCP × Biotech × CRO × Foxu.AI: Launch of Industrialized Scenarios for Trusted Knowledge Delivery
How Will AI Reshape the Relationship Between Pharma Companies and CRO/CMO in the Next Three Years?
Tong Guo, CEO of Clinical Research Center,GoBroad Healthcare Group
Bingshi Guo, General Manager of Macromolecule R&D Platform, Jeyou Pharma
Hui Zhou, Senior Vice President & Chief R&D Officer for Oncology Pipeline, Innovent Biologics
Lin Xia, Former Senior Reviewer of CDE; Deputy General Manager of TriApex Laboratories & CMO of TriApex (Nanjing)
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
